This Obesity Stock Could More Than Double Over the Next 12 Months, According to Wall Street

Viking Therapeutics has a Wall Street consensus 12-month price target of $93.59, more than 170% above its current price, reflecting continued bullishness despite last year’s setback in the oral VK2735 program. The injectable VK2735 delivered up to 14.7% weight loss in 13 weeks, and analysts expect a major Phase 3 update next year with potential FDA approval no later than 2029. The article frames Viking as a credible challenger in a weight-loss market expected to grow from $26 billion to over $130 billion annually by 2031.

Analysis

VKTX is increasingly a time-arbitrage trade: the market is discounting a binary pharma outcome too early, while the setup still has multiple interim catalysts that can re-rate the name long before any regulatory event. The key edge is not simply "another GLP-1," but the possibility that a differentiated tolerability/maintenance profile lets Viking capture a higher-retention segment of the obesity market that the current leaders are structurally weaker at serving. If that thesis gains traction, the upside is less about displacement and more about becoming the default second-line / maintenance standard.

The second-order winner is likely the service ecosystem around obesity care: telehealth prescribers, compounding-distribution intermediaries, and specialty pharmacy channels that benefit from a broader menu of therapies and dosing strategies. For incumbents NVO and LLY, the threat is not immediate share loss in the current injectable channel, but margin pressure as the market shifts from scarcity pricing to a more competitive, retention-driven market where convenience, tolerability, and adherence matter more than pure first-mover brand strength. That tends to compress the premium multiple on category leaders even if unit growth stays healthy.

The main risk is timeline slippage: this remains a pre-revenue biotech with multiple ways to disappoint before the market gets the next major readout. The stock can rerate hard on interim data, but it can also de-rate 30-50% on any signal that oral conversion, maintenance dosing, or tolerability still fails to solve the real commercial problem. The consensus appears to be pricing a favorable trial path in 2025-2026 and FDA optionality beyond that; what it may be missing is that the most valuable outcome is not peak efficacy, but a durable treatment algorithm that physicians can actually prescribe at scale.

Contrarianly, the move may be underpriced if investors are still anchoring VKTX to the failed-oral-drug narrative. If Viking can prove a lower-dose oral maintenance role, the market could assign platform value rather than single-asset value, which is a very different multiple regime. That makes the stock more attractive as a catalyst-driven long than as a fundamental hold; the setup is for volatility expansion, not a smooth compounding story.

Key Decisions for Investors

• Buy VKTX on weakness ahead of the next major trial update over the next 3-6 months; target a catalyst-driven re-rating into the readout, with risk capped by a hard stop if the market starts pricing in another oral-dropout failure.
• Use a call spread in VKTX for the next 6-12 months rather than common stock if you want convexity: upside is tied to interim data, while downside is defined if the next update disappoints.
• Pair trade: long VKTX / short a basket of obesity incumbents on a relative basis only if you expect differentiation to matter more than category growth; this works best as a 3-9 month trade into data, not a long-term structural short.
• Reduce exposure to NVO/LLY into strength if obesity multiple expansion is the main driver of your thesis; the market may begin to price a slower margin mix as competition shifts from scarcity to retention and maintenance.